33 results
DEF 14C
BGLC
BioNexus Gene Lab Corp
29 Feb 24
Information statement
5:16pm
paid:
Fee paid previously with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2 … An Address
If hard copies of the materials are requested, we will send only one Information Statement and other corporate mailings to stockholders who share
PRE 14C
BGLC
BioNexus Gene Lab Corp
26 Jan 24
Preliminary information
4:05pm
paid:
Fee paid previously with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2 … An Address
If hard copies of the materials are requested, we will send only one Information Statement and other corporate mailings to stockholders who
8-K
EX-1.1
BGLC
BioNexus Gene Lab Corp
24 Jul 23
BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:28pm
Disclosure Materials. Other than the Registration Statement, the Pricing Disclosure Package, the Final Prospectus, each Preliminary Prospectus, and each … Subsidiary and each Subsidiary’s ownership and control of other Subsidiaries, is as described in the Registration Statement, the Disclosure Materials
8-K
EX-99.1
BGLC
BioNexus Gene Lab Corp
24 Jul 23
BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:28pm
raw materials in the Southeast Asia region and the development of safe, effective, and non-invasive liquid biopsy tests for early diagnosis … .
Furthermore, through our wholly owned subsidiary Chemrex Corporation Sdn Bhd., we focus on selling chemical raw materials for manufacturing industrial
8-K
EX-99.2
ll5lj x82mmedijr
24 Jul 23
BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:28pm
424B4
5qo9zbvk oc8f
21 Jul 23
Prospectus supplement with pricing info
3:37pm
DEF 14C
kou02kjustv33en
17 May 23
Information statement
9:07am